Tango Therapeutics (TNGX) Expected to Post Earnings on Tuesday

Tango Therapeutics (NASDAQ:TNGX) is projected to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Tango Therapeutics to post earnings of ($0.3530) per share and revenue of $3.28 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts expect Tango Therapeutics to post ($1.41) EPS for the current fiscal year and ($1.60) EPS for the next fiscal year.

Tango Therapeutics Trading Down 4.9%

TNGX stock opened at $22.19 on Tuesday. Tango Therapeutics has a fifty-two week low of $7.12 and a fifty-two week high of $34.39. The stock has a fifty day moving average of $23.85 and a 200-day moving average of $21.94.

Insider Activity at Tango Therapeutics

In other news, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at approximately $2,832,231.21. This trade represents a 18.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the transaction, the insider directly owned 59,121 shares in the company, valued at approximately $1,431,910.62. The trade was a 12.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on TNGX shares. Guggenheim upped their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings upgraded Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen lowered Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Mizuho boosted their target price on Tango Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Finally, HC Wainwright boosted their target price on Tango Therapeutics from $66.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $44.62.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.